


CLAIMS

What is claimed is:

1. A combination of one or more IK_r channel blockers and of one or more
5 compounds of the formula Ia or Ib



or physiologically tolerable salts thereof,

10 in which

R(1) is alkyl having 3, 4 or 5 carbon atoms or quinolinyl,

R(2) is alkyl having 1, 2, 3 or 4 carbon atoms or cyclopropyl;

R(3) is phenyl or pyridyl,

where phenyl and pyridyl are unsubstituted or substituted by 1 or 2

15 substituents selected from the group consisting of F, Cl, CF_3 , OCF_3 , alkyl having 1, 2 or 3 carbon atoms and alkoxy having 1, 2 or 3 carbon atoms;

A is $-C_nH_{2n-}$;

n is 0, 1 or 2;

R(4), R(5), R(6) and R(7)

20 independently of one another are hydrogen, F, Cl, CF_3 , OCF_3 , CN, alkyl having 1, 2 or 3 carbon atoms, or alkoxy having 1, 2 or 3 carbon atoms;

B is $-C_mH_{2m-}$;

m is 1 or 2;

R(8) is alkyl having 2 or 3 carbon atoms, phenyl or pyridyl,

where phenyl and pyridyl are unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, CF₃, OCF₃, alkyl having 1, 2 or 3 carbon atoms and alkoxy having 1, 2 or 3 carbon atoms;

R(9) is C(O)OR(10) or COR(10);

5 R(10) is -C_xH_{2x}-R(11);

x is 0, 1 or 2; and

R(11) is phenyl,

where phenyl is unsubstituted or substituted by 1 or 2 substituents selected from the group consisting of F, Cl, CF₃, OCF₃, alkyl having 1, 2 or 3 carbon atoms and alkoxy having 1, 2 or 3 carbon atoms

2. The combination as claimed in claim 1, wherein the IK_r blockers are selected from the group consisting of

15 dofetilide, ibutilide, almokalant, dl-sotalol, d-sotalol, azimilide, amiodarone, E4031, clofilium, ambasilide, MS551, tedisamil, bertosamil and quinidine.

3. The combination as claimed in claim 2, the IK_r blockers being selected from the group consisting of

20 dofetilide, ibutilide, almokalant, dl-sotalol, d-sotalol, amiodarone and quinidine.

4. The combination as claimed in claim 1, the IK_r blockers being selected from the group consisting of

dofetilide, ibutilide, almokalant, dl-sotalol, d-sotalol, amiodarone and quinidine and
25 the compounds of the formula Ia or Ib being selected from the group consisting of
2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide,

2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)-ethylamide,

30 2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid 2,4-difluorobenzylamide,

(S)-2'-(α -methylbenzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)ethylamide,

2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide,

2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide,

5 (S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and their physiologically tolerable salts.

5. The combination as claimed in claim 1, comprising:

10 2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and ibutilide,

2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and dofetilide,

2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and amiodarone,

15 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide and ibutilide,

2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide and dofetilide,

20 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide and amiodarone,

2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide and ibutilide,

2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide and dofetilide,

25 2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide and amiodarone,

(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and ibutilide,

30 (S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and dofetilide,

(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and amiodarone,
or the physiologically tolerable salts thereof.

- 5 6. A pharmaceutical preparation comprising a combination as claimed in claim 1
as active compound, together with pharmaceutically acceptable vehicles or
additives and, optionally, one or more other pharmacologically active compounds.
- 10 7. A pharmaceutical product comprising one or more IK_r channel blockers
together with one or more compounds of the formula Ia or Ib, or physiologically
tolerable salts thereof, as set forth in claim 1 for simultaneous, separate or
sequential administration for the therapy or prophylaxis of atrial fibrillation or atrial
flutters.
- 15 8. A method for the therapy or prophylaxis of atrial fibrillation or atrial flutters
comprising the simultaneous, separate or sequential administration of a
combination as claimed in claim 1.
- 20 9. The method as claimed in claim 8, wherein in said combination the IK_r
blockers are selected from the group consisting of
dofetilide, ibutilide, almokalant, dl-sotalol, d-sotalol, azimilide, amiodarone, E4031,
clofilium, ambasilide, MS551, tedisamil, bertosamil and quinidine.
- 25 10. The method as claimed in claim 9, wherein in said combination the IK_r
blockers are selected from the group consisting of
dofetilide, ibutilide, almokalant, dl-sotalol, d-sotalol, amiodarone and quinidine.
- 30 11. The method as claimed in claim 8, wherein in said combination the IK_r
blockers are selected from the group consisting of dofetilide, ibutilide, almokalant,
dl-sotalol, d-sotalol, amiodarone and quinidine and the compounds of the formula Ia
or Ib are selected from the group consisting of

2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide,

2'-(benzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)-ethylamide,

5 2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid 2,4-difluorobenzylamide,

(S)-2'-(α -methylbenzyloxycarbonylaminomethyl)biphenyl-2-carboxylic acid 2-(2-pyridyl)ethylamide,

2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide,

10 2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide,
(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide
and their physiologically tolerable salts.

12. The method as claimed in claim 8, the combination comprising:

15 2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and ibutilide,

2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and dofetilide,

20 2'-{[2-(4-methoxyphenyl)acetylamino]methyl}biphenyl-2-carboxylic acid (2-pyridin-3-ylethyl)amide and amiodarone,

2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide and ibutilide,

2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide and dofetilide,

25 2-(butyl-1-sulfonylamino)-N-[1(R)-(6-methoxypyridin-3-yl)propyl]benzamide and amiodarone,

2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide and ibutilide,

30 2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide and dofetilide,

2-(butyl-1-sulfonylamino)-N-(cyclopropylpyridin-3-ylmethyl)-5-methylbenz-amide
and amiodarone,

(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and
ibutilide,

5 (S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and
dofetilide,

(S)-5-fluoro-2-(quinoline-8-sulfonylamino)-N-(1-phenylpropyl)benzamide and
amiodarone,

or the physiologically tolerable salts thereof.